OBI Pharma, Inc. (TPEX:4174)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
44.05
-1.05 (-2.33%)
Feb 11, 2026, 1:30 PM CST
Market Cap5.93B -60.9%
Revenue (ttm)49.29M -29.1%
Net Income-2.36B
EPS-18.24
Shares Out131.48M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume594,773
Average Volume532,936
Open45.10
Previous Close45.10
Day's Range44.05 - 45.10
52-Week Range44.05 - 127.80
Beta0.27
RSI29.69
Earnings DateMar 27, 2026

About OBI Pharma

OBI Pharma, Inc., a clinical stage oncology company, research and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company’s pipeline products include Adagloxad simolenin which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424 which has completed phase 2 for the treatment of liver hepatocellular carcinoma and acute lymphocytic leukemia; OBI-992 which is in phase 1 for the treatment of so... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4174
Full Company Profile

Financial Performance

In 2024, OBI Pharma's revenue was 62.68 million, an increase of 50.85% compared to the previous year's 41.55 million. Losses were -2.31 billion, 120.7% more than in 2023.

Financial Statements